Synageva BioPharma™ to Host 2012 Fourth Quarter and Full Year Financial Results Conference Call on March 11

  Synageva BioPharma™ to Host 2012 Fourth Quarter and Full Year Financial
  Results Conference Call on March 11

Business Wire

LEXINGTON, Mass. -- March 1, 2013

Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare diseases,
will report 2012 fourth quarter and full year financial results after the
NASDAQ Market closes on Monday, March 11, 2013. Synageva management will
conduct a conference call and audio webcast to discuss these results as well
as provide a general business update at 4:30 p.m. EST on the same day.

The dial-in number for the conference call is (877) 312-5514 for U.S. callers,
or (970) 315-0452 for international callers, and reference conference ID:
95417172. A live webcast of the call will be available from the “Webcasts &
Presentations” section of the Investor Relations tab on the home page of
Synageva’s website at www.synageva.com.

About Synageva’s Lead Program

Sebelipase alfa (SBC-102) is a recombinant form of the human LAL enzyme under
development by Synageva as an enzyme replacement therapy for LAL Deficiency, a
lysosomal storage disorder (LSD). Synageva is currently evaluating sebelipase
alfa in global clinical trials for both early and late onset LAL Deficiency.
Sebelipase alfa has been granted orphan designations by the U.S. Food and Drug
Administration (FDA), the European Medicines Agency, and the Japanese Ministry
of Health, Labour and Welfare. Additionally, sebelipase alfa received “fast
track” designation by the FDA.

About LAL Deficiency

LAL Deficiency is a rare autosomal recessive LSD caused by a marked decrease
in LAL enzyme activity. Late onset LAL Deficiency, sometimes called
Cholesteryl Ester Storage Disease (CESD), affects both children and adults. In
these patients, the buildup of fatty material in the liver and blood vessel
walls may lead to liver cirrhosis, liver failure and accelerated
atherosclerotic events. Early onset LAL Deficiency, sometimes called Wolman
disease, affects infants and is characterized by severe malabsorption, growth
failure and liver failure, and is usually fatal within the first six months of
life. There are no approved pharmacological therapies for LAL Deficiency.
Success with stem cell and liver transplant appears to be limited by
procedure-related morbidity and mortality.

About Synageva BioPharma Corp.

Synageva is a clinical stage biopharmaceutical company focused on the
discovery, development, and commercialization of therapeutic products for
patients with life-threatening rare diseases and unmet medical need. Synageva
has several protein therapeutics in its drug development pipeline. The company
has a team with a proven record of bringing therapies to patients with rare
diseases.

Further information regarding Synageva BioPharma Corp. is available at
www.synageva.com.

Forward-Looking Statements

This news release and oral statements made from time to time by Synageva
representatives in respect of the same subject matter may contain
“forward-looking statements” under the provisions of the Private Securities
Litigation Reform Act of 1995. Such statements can be identified by
introductory words such as “expects,” “plans,” “intends,” “believes,” “will,”
“estimates,” “forecasts,” “projects,” or words of similar meaning and by the
fact that they do not relate strictly to historical or current facts. Many
factors may cause actual results to differ materially from forward-looking
statements, including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known, including those identified under the
heading “Risk Factors” in the Company’s prospectus supplement filed with the
Securities and Exchange Commission (the “SEC”) on January3, 2013, and other
filings Synageva periodically makes with the SEC and others of which are not.

“Dedicated to Rare Diseases®” is a registered trademark and “Synageva
BioPharma™” is a trademark of Synageva BioPharma Corp.

Contact:

Contact for Synageva:
Matthew Osborne, 781-357-9947
matthew.osborne@synageva.com
 
Press spacebar to pause and continue. Press esc to stop.